Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
87352574 |
LAW OFFICE ASSIGNED |
LAW OFFICE 101 |
MARK SECTION |
MARK FILE NAME |
http://uspto.report/TM/87352574/mark.png |
LITERAL ELEMENT |
TEVA |
STANDARD CHARACTERS |
NO |
USPTO-GENERATED IMAGE |
NO |
COLOR(S) CLAIMED
(If applicable) |
The color(s) white, light green and dark green is/are claimed as a feature of the mark. |
DESCRIPTION OF THE MARK
(and Color Location, if applicable) |
The mark consists of a light green design that begins at the bottom left hand corner and rises up to the upper right hand corner. This light
green continues in a straight light across the top. There are 2 darker green half circles at the bottom right hand corner that when they intersect make a dark green. In the dark green intersection at
the bottom right hand corner is the word teva in lower case white letters. The v in the word teva is formed by 2 leaf shapes. |
GOODS AND/OR SERVICES SECTION (current) |
INTERNATIONAL CLASS |
005 |
DESCRIPTION |
Pharmaceutical products |
FILING BASIS |
Section 1(b) |
GOODS AND/OR SERVICES SECTION (proposed) |
INTERNATIONAL CLASS |
005 |
TRACKED TEXT DESCRIPTION |
Pharmaceutical products; Pharmaceutical preparations for the
prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of
diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention
and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention
and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract,
gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and
disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical
preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of
urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote
bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical
preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy
preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central
nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory
organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous
system. |
FINAL DESCRIPTION |
Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and
treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic
neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable
bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis;
Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and
disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention
and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and
treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for
the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote
bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely,
contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical
preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory
organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system. |
FILING BASIS |
Section 1(b) |
ADDITIONAL STATEMENTS SECTION |
COLOR(S) CLAIMED
(If applicable) |
The color(s) white and gray is/are claimed as a feature of the mark. |
DESCRIPTION OF THE MARK
(and Color Location, if applicable) |
The mark consists of a light green design that begins at the bottom left hand corner and rises up to the upper right hand corner. This light
green continues in a straight light across the top. There are 2 darker green half circles at the bottom right hand corner that when they intersect make a dark green. In the dark green intersection at
the bottom right hand corner is the word teva in lower case white letters. The v in the word teva is formed by 2 leaf shapes. The color white also appears in the rectangle created by the gray
outlining the entire mark. The entire mark is outlined by a thin gray line. |
TRANSLATION |
The English translation of TEVA in the mark is NATURE. |
MISCELLANEOUS STATEMENT |
|
MISCELLANEOUS FILE NAME(S) |
ORIGINAL PDF FILE |
mis-681771705-20171114123605485199_._USPTO_DEC.pdf |
CONVERTED PDF FILE(S)
(5 pages) |
\\TICRS\EXPORT17\IMAGEOUT17\873\525\87352574\xml5\ROA0002.JPG |
|
\\TICRS\EXPORT17\IMAGEOUT17\873\525\87352574\xml5\ROA0003.JPG |
|
\\TICRS\EXPORT17\IMAGEOUT17\873\525\87352574\xml5\ROA0004.JPG |
|
\\TICRS\EXPORT17\IMAGEOUT17\873\525\87352574\xml5\ROA0005.JPG |
|
\\TICRS\EXPORT17\IMAGEOUT17\873\525\87352574\xml5\ROA0006.JPG |
SIGNATURE SECTION |
RESPONSE SIGNATURE |
/herschel perel/ |
SIGNATORY'S NAME |
Herschel Perel |
SIGNATORY'S POSITION |
Director, Global Trademarks |
SIGNATORY'S PHONE NUMBER |
215-293-6406 |
DATE SIGNED |
11/14/2017 |
AUTHORIZED SIGNATORY |
YES |
FILING INFORMATION SECTION |
SUBMIT DATE |
Tue Nov 14 13:07:44 EST 2017 |
TEAS STAMP |
USPTO/ROA-XX.XXX.XXX.X-20
171114130744166468-873525
74-5108e0f617793d1299d17e
58c66deb79af529d732832338
f2aae914f62d1115-N/A-N/A-
20171114123605485199 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1957 (Rev 10/2011) |
OMB No. 0651-0050 (Exp 09/20/2020) |
Response to Office Action
To the Commissioner for Trademarks:
Application serial no.
87352574 TEVA (Stylized and/or with Design, see http://uspto.report/TM/87352574/mark.png) has been amended as follows:
CLASSIFICATION AND LISTING OF GOODS/SERVICES
Applicant proposes to amend the following class of goods/services in the application:
Current: Class 005 for Pharmaceutical products
Original Filing Basis:
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
Proposed:
Tracked Text Description: Pharmaceutical products;
Pharmaceutical preparations for the prevention and treatment of
Alzheimer's disease;
Pharmaceutical preparations for the prevention and treatment of depression;
Pharmaceutical
preparations for the prevention and treatment of psychological disorders;
Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic
neuropathy;
Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders;
Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome;
Pharmaceutical preparations for the prevention and treatment
of neurodegenerative diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of osteoporosis;
Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain;
Pharmaceutical preparations for the prevention and treatment
of peripheral nervous system diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and
dermatological diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of sexual dysfunction;
Pharmaceutical preparations for the
prevention and treatment of symptoms associated with uterine fibroids;
Pharmaceutical preparations for the prevention and treatment of urinary incontinence and
overactive bladder;
Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders;
Pharmaceutical preparations that support, encourage and promote bone strength;
Pharmaceutical preparations that support, encourage and promote bone
health;
Pharmaceutical preparations used in the treatment of bone disorders and bone diseases;
Pharmaceutical
preparations, namely injectable contraceptives;
Pharmaceutical preparations, namely, contraceptive preparations;
Pharmaceutical preparations, namely fertility enhancement preparations;
Pharmaceutical preparations, namely, hormone replacement therapy
preparations;
Pharmaceutical preparations for the treatment of cancer;
Pharmaceutical agents affecting the central
nervous system;
Pharmaceutical agents affecting circulatory systems;
Pharmaceutical agents affecting sensory
organs;
Pharmaceutical agents affecting urogenital organs;
Pharmaceutical agents affecting peripheral nervous
system.Class 005 for Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression;
Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy;
Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome;
Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical
preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders;
Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and
treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and
treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for
the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote
bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely,
contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical
preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory
organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system.
Filing Basis: Section 1(b), Intent to Use: For a trademark or service mark application: As of the application filing date, the applicant had a bona fide intention, and was
entitled, to use the mark in commerce on or in connection with the identified goods/services in the application.
For a collective trademark, collective service mark, or collective membership
mark application: As of the application filing date, the applicant had a bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by members
on or in connection with the identified goods/services/collective membership organization.
For a certification mark application: As of the application filing date, the applicant had a
bona fide intention, and was entitled, to exercise legitimate control over the use of the mark in commerce by authorized users in connection with the identified goods/services, and the applicant will
not engage in the production or marketing of the goods/services to which the mark is applied, except to advertise or promote recognition of the certification program or of the goods/services that
meet the certification standards of the applicant.
ADDITIONAL STATEMENTS
Color Claim
The color(s) white and gray is/are claimed as a feature of the mark.
Description of mark
The mark consists of a light green design that begins at the bottom left hand corner and rises up to the upper right hand corner. This light green continues in a straight light across the top. There
are 2 darker green half circles at the bottom right hand corner that when they intersect make a dark green. In the dark green intersection at the bottom right hand corner is the word teva in lower
case white letters. The v in the word teva is formed by 2 leaf shapes. The color white also appears in the rectangle created by the gray outlining the entire mark. The entire mark is outlined by a
thin gray line.
Translation
The English translation of TEVA in the mark is NATURE.
Miscellaneous Statement
Original PDF file:
mis-681771705-20171114123605485199_._USPTO_DEC.pdf
Converted PDF file(s) ( 5 pages)
Miscellaneous File1
Miscellaneous File2
Miscellaneous File3
Miscellaneous File4
Miscellaneous File5
SIGNATURE(S)
Response Signature
Signature: /herschel perel/ Date: 11/14/2017
Signatory's Name: Herschel Perel
Signatory's Position: Director, Global Trademarks
Signatory's Phone Number: 215-293-6406
The signatory has confirmed that he/she is a Canadian attorney/agent, or an associate thereof, who represents an owner/holder located in Canada; that he/she is either registered with the USPTO and in
good standing as a patent agent under 37 C.F.R. §11.6(c) or he/she has been granted reciprocal recognition under 37 C.F.R. §11.14(c) by the USPTO's Office of Enrollment and Discipline; and, that to
the best of his/her knowledge, if prior to his/her appointment another Canadian attorney/agent or a U.S. attorney not currently associated with his/her company/firm previously represented the
owner/holder in this matter: (1) the owner/holder has filed or is concurrently filing a signed revocation of or substitute power of attorney with the USPTO; (2) the USPTO has granted the request of
the prior representative to withdraw; (3) the owner/holder has filed a power of attorney appointing him/her in this matter; or (4) the owner's/holder's appointed Canadian attorney/agent or U.S.
attorney has filed a power of attorney appointing him/her as an associate attorney in this matter.
Serial Number: 87352574
Internet Transmission Date: Tue Nov 14 13:07:44 EST 2017
TEAS Stamp: USPTO/ROA-XX.XXX.XXX.X-20171114130744166
468-87352574-5108e0f617793d1299d17e58c66
deb79af529d732832338f2aae914f62d1115-N/A
-N/A-20171114123605485199